Brief: Moonlake Immunotherapeutics Reports On Week 16 Results Of The Vela Phase 3 Hidradenitis Suppurativa Program With The Nanobody® Sonelokimab
28/09/2025 17:08
Sept 28 (Reuters) - MoonLake Immunotherapeutics MLTX.O: MOONLAKE IMMUNOTHERAPEUTICS REPORTS ON WEEK 16 RESULTS OF THE VELA PHASE 3 HIDRADENITIS SUPPURATIVA PROGRAM WITH THE NANOBODY® SONELOKIMAB MOONLAKE IMMUNOTHERAPEUTICS - SONELOKIMAB SHOWS SIGNIFICANT IMPROVEMENT ACROSS ALL PRIMARY & KEY SECONDARY ENDPOINTS IN VELA TRIALS Source text: ID:nGNE2C2CL4 Further company coverage: MLTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial